{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:43:28Z","timestamp":1789461808337,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022513","name":"Tasmanian Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000950","name":"Cancer Council South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020670","name":"Cancer Council Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["511335"],"award-info":[{"award-number":["511335"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jrnjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Renal Nutrition"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1053\/j.jrn.2026.01.008","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:25:38Z","timestamp":1770164738000},"page":"491-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of L-Carnitine for the Treatment of Erythropoietin-Resistant Renal Anemia: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial"],"prefix":"10.1053","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-7287","authenticated-orcid":false,"given":"Stephanie E.","family":"Reuter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5948-7675","authenticated-orcid":false,"given":"Alison L.","family":"Steiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall J.","family":"Faull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5094-098X","authenticated-orcid":false,"given":"Allan M.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.jrn.2026.01.008_bib1","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S0272-6386(03)00114-8","article-title":"L-carnitine treatment of anemia","volume":"41","author":"Golper","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2026.01.008_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ndt\/10.supp2.62","article-title":"R-HuEPO hyporesponsiveness - who and why?","volume":"10","author":"Drueke","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jrn.2026.01.008_bib3","doi-asserted-by":"crossref","first-page":"992","DOI":"10.7326\/0003-4819-111-12-992","article-title":"Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial","volume":"111","author":"Eschbach","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.jrn.2026.01.008_bib4","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0272-6386(04)01086-8","article-title":"Epoetin requirements predict mortality in hemodialysis patients","volume":"44","author":"Zhang","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2026.01.008_bib5","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0272-6386(89)80148-9","article-title":"Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients","volume":"14","author":"Wolcott","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2026.01.008_bib7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1258\/0004563054889954","article-title":"Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease","volume":"42","author":"Reuter","year":"2005","journal-title":"Ann Clin Biochem"},{"key":"10.1053\/j.jrn.2026.01.008_bib8","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0272-6386(03)00113-6","article-title":"Dialysis-related carnitine disorder and levocarnitine pharmacology","volume":"41","author":"Evans","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2026.01.008_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF03261931","article-title":"Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects","volume":"51","author":"Reuter","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.jrn.2026.01.008_bib10","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/ndt\/gfn588","article-title":"Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients","volume":"24","author":"Reuter","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jrn.2026.01.008_bib11","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0272-6386(03)00110-0","article-title":"Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference","volume":"41","author":"Eknoyan","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2026.01.008_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1440-1797.2007.00817.x","article-title":"L-carnitine supplementation in the dialysis population - are Australian patients missing out?","volume":"13","author":"Reuter","year":"2007","journal-title":"Nephrology"},{"key":"10.1053\/j.jrn.2026.01.008_bib14","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3390\/nu13041219","article-title":"Significance of levocarnitine treatment in dialysis patients","volume":"13","author":"Takashima","year":"2021","journal-title":"Nutrients"},{"key":"10.1053\/j.jrn.2026.01.008_bib15","first-page":"302","article-title":"Endocrine-metabolic effects of L-carnitine in patients on regular dialysis treatment","volume":"19","author":"Albertazzi","year":"1983","journal-title":"Proc Eur Dial Transplant Assoc"},{"key":"10.1053\/j.jrn.2026.01.008_bib16","first-page":"368","article-title":"Effect of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children: about two cases","volume":"62","author":"B\u00e9rard","year":"1992","journal-title":"Nephron"},{"key":"10.1053\/j.jrn.2026.01.008_bib17","first-page":"314","article-title":"Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease","volume":"73","author":"Boran","year":"1996","journal-title":"Nephron"},{"key":"10.1053\/j.jrn.2026.01.008_bib18","first-page":"498","article-title":"Effects of L-carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin: a pilot study","volume":"27","author":"Caruso","year":"1998","journal-title":"Dial Transplant"},{"key":"10.1053\/j.jrn.2026.01.008_bib19","first-page":"620","article-title":"Effects of L-carnitine on chronic anemia and erythrocyte adenosine triphosphate concentration in hemodialyzed patients","volume":"41","author":"Donatelli","year":"1987","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1053\/j.jrn.2026.01.008_bib20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0272-6386(96)90147-X","article-title":"L-carnitine and erythropoietin requirements in hemodialysis patients","volume":"28","author":"Kavadias","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2026.01.008_bib21","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1038\/sj.ki.4490857","article-title":"Anemia and carnitine supplementation in hemodialyzed patients","volume":"55","author":"Kletzmayr","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2026.01.008_bib22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/0272-6386(95)90439-5","article-title":"L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin","volume":"26","author":"Labonia","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2026.01.008_bib23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/ki.1987.271","article-title":"Effects of L-carnitine on sodium transport in erythrocytes from dialyzed uremic patients","volume":"32","author":"Labonia","year":"1987","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2026.01.008_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000014474","article-title":"Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin","volume":"19","author":"Matsumoto","year":"2001","journal-title":"Blood Purif"},{"key":"10.1053\/j.jrn.2026.01.008_bib25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1185\/030079902125000606","article-title":"Beneficial effects of L-carnitine in dialysis patients with impaired left ventricular function: an observational study","volume":"18","author":"Romagnoli","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.jrn.2026.01.008_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1081\/JDI-100100853","article-title":"Effect of L-carnitine supplementation on red blood cells deformability in hemodialysis patients","volume":"22","author":"Sotirakopoulos","year":"2000","journal-title":"Ren Fail"},{"key":"10.1053\/j.jrn.2026.01.008_bib27","first-page":"209","article-title":"Body composition and long-term levo-carnitine supplementation","volume":"149","author":"Trovato","year":"1998","journal-title":"Clin Ter"},{"key":"10.1053\/j.jrn.2026.01.008_bib28","first-page":"1042","article-title":"Long-term L-carnitine treatment of chronic anaemia of patients with end-stage renal disease","volume":"31","author":"Trovato","year":"1982","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1053\/j.jrn.2026.01.008_bib29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000045993","article-title":"Effect of L-carnitine supplementation in hemodialysis patients","volume":"88","author":"Vesel\u00e1","year":"2001","journal-title":"Nephron"},{"key":"10.1053\/j.jrn.2026.01.008_bib30","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1038\/ki.2008.523","article-title":"Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality","author":"Lopez-Gomez","year":"2008","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.jrn.2026.01.008_bib31","series-title":"Carnitine metabolism and human nutrition","article-title":"Carnitine metabolism and nutrition in dialysis patients","author":"Brass","year":"2014"},{"key":"10.1053\/j.jrn.2026.01.008_bib32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000089450","article-title":"Debate forum: carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy","volume":"24","author":"Handelman","year":"2006","journal-title":"Blood Purif"},{"key":"10.1053\/j.jrn.2026.01.008_bib33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000089449","article-title":"Debate forum: levocarnitine therapy is rational and justified in selected dialysis patients","volume":"24","author":"Schreiber","year":"2006","journal-title":"Blood Purif"},{"key":"10.1053\/j.jrn.2026.01.008_bib34","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1681\/ASN.V133708","article-title":"Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review","volume":"13","author":"Hurot","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2026.01.008_bib35","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s11255-021-02835-5","article-title":"Effect of L-carnitine supplementation on renal anemia in patients on hemodialysis: a meta-analysis","volume":"53","author":"Zhu","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"10.1053\/j.jrn.2026.01.008_bib36","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1053\/j.ajkd.2010.05.009","article-title":"Analytical and biological variation in measures of anemia and iron status in patients treated with maintenance hemodialysis","volume":"56","author":"Van Wyck","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2026.01.008_bib38","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/ndt\/gfr334","article-title":"Altered carnitine metabolism in dialysis patients with reduced physical function may be due to dysfunctional fatty acid oxidation","volume":"27","author":"Murphy","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jrn.2026.01.008_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/014860710603000110","article-title":"Carnitine treatment improved quality-of-life measure in a sample of midwestern hemodialysis patients","volume":"30","author":"Steiber","year":"2006","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1053\/j.jrn.2026.01.008_bib40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/00031305.1988.10475530","article-title":"Maximum Z scores and outliers","volume":"42","author":"Shiffler","year":"1988","journal-title":"Am Stat"},{"key":"10.1053\/j.jrn.2026.01.008_bib41","article-title":"Association between changes in hemoglobin concentration and cardiovascular risks and all-cause mortality among young women","volume":"7","author":"Lee","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jrn.2026.01.008_bib42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/hdi.12021","article-title":"What is the value of L-carnitine level determination for carnitine supplementation in hemodialysis patients?","volume":"17","author":"Reuter","year":"2013","journal-title":"Hemodial Int"},{"key":"10.1053\/j.jrn.2026.01.008_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0005-2736(89)90275-7","article-title":"Effects of L-carnitine and palmitoylcarnitine on membrane fluidity of human erythrocytes","volume":"986","author":"Kobayashi","year":"1989","journal-title":"Biochim Biophys Acta"},{"key":"10.1053\/j.jrn.2026.01.008_bib44","first-page":"574","article-title":"Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients","volume":"72","author":"Matsumura","year":"1996","journal-title":"Nephron"}],"container-title":["Journal of Renal Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051227626000117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051227626000117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T20:37:00Z","timestamp":1780864620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051227626000117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1051227626000117"],"URL":"https:\/\/doi.org\/10.1053\/j.jrn.2026.01.008","relation":{},"ISSN":["1051-2276"],"issn-type":[{"value":"1051-2276","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of L-Carnitine for the Treatment of Erythropoietin-Resistant Renal Anemia: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Renal Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jrn.2026.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}